High-Throughput Drug Screening in a Cellular Model of KRAS-Driven Arteriovenous Malformations

  • J Invest Dermatol. 2025 Mar 22:S0022-202X(25)00330-6. doi: 10.1016/j.jid.2025.02.151.
Fanourios Michailidis  1 ,  Davide Zecchin  2 ,  Mohammad Rabii  1 ,  Ignacio Del Valle Torres  1 ,  Aimie Sauvadet  1 ,  Ming Jiang  3 ,  Michael Howell  3 ,  Dale Bryant  1 ,  Satyamaanasa Polubothu  4 ,  Veronica A Kinsler  5
Affiliations
  • 1. Mosaicism and Precision Medicine Laboratory, Francis Crick Institute, London, United Kingdom; Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
  • 2. Institute of Ophthalmology, University College London, London, United Kingdom.
  • 3. High Throughput Screening Facility, Francis Crick Institute, London, United Kingdom.
  • 4. Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, United Kingdom; Paediatric Dermatology, Great Ormond Street Hospital for Children, London, United Kingdom.
  • 5. Mosaicism and Precision Medicine Laboratory, Francis Crick Institute, London, United Kingdom; Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, United Kingdom; Paediatric Dermatology, Great Ormond Street Hospital for Children, London, United Kingdom. Electronic address: [email protected].
PMID: 40122156 DOI: 10.1016/j.jid.2025.02.151
Keywords
AVM; Mosaic disorders; Oncogene; Therapeutics; Vascular anomaly.
Products